Antengene announces nmpa approval of ind application for atg-019 in patients with advanced solid tumors or non-hodgkin's lymphoma

Shanghai and hong kong, april 5, 2021 /prnewswire/ -- antengene corporation limited ("antengene", sehk: 6996.hk), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that the national medical products administration (nmpa) has approved the investigational new drug (ind) application for a phase i clinical trial to evaluate safety and toler ability of atg-019 (monotherapy or combined with niacin er) in patients with advanced solid tumors or non-hodgkin's lymphoma (nhl) in china. as an orally bioavailable dual pak4/nampt inhibitor, atg-019 can lead to antitumor effects through energy depletion, inhibition of dna repair, cell cycle arrest, inhibition of proliferation, and ultimately cell apoptosis.
KPTI Ratings Summary
KPTI Quant Ranking